GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Operating Income 2022–2026

Name: GlaxoSmithKline Pharmaceuticals Limited (GLAXO) operating income history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

GlaxoSmithKline Pharmaceuticals Limited annual operating income for fiscal 2026 was ₹12.5 billion, an increase of 12.0% from ₹11.1 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GLAXO Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Income (EBIT)	₹12.5B	₹11.1B	₹8.4B	₹7.5B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GLAXO Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Operating Income (EBIT)	₹2.8B	₹3.4B	₹3.5B	₹2.4B	₹3.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

4568 Operating Income — Daiichi Sankyo Company, Limited
4503 Operating Income — Astellas Pharma Inc.
4528 Operating Income — Ono Pharmaceutical Co., Ltd.
4536 Operating Income — Santen Pharmaceutical Co., Ltd.
RUBICON Operating Income — Rubicon Research Limited
NOVN Operating Income — Novartis AG

More GLAXO metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All GLAXO financial statements → Interactive GLAXO charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.